Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial

经皮射频消融与微波消融治疗肝细胞癌:一项随机对照试验

阅读:1

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third most common cause of cancer related deaths. Radiofrequency ablation (RFA) and microwave ablation (MWA) are effective measures for HCC management. Although MWA is usually considered to be superior to RFA in the medical community, clinical studies showed contradictory results. We aimed to compare the efficacy of both techniques using a randomized controlled trial. METHODS: We had assessed all patients with definite HCC who were referred to our unit during the period from mid-June 2017 to mid-December 2017 for inclusion in the study. After fulfilling the criteria, patients were randomized to either RFA or MWA. Achieving complete ablation was ensured. Patients were followed up every 3 months after the procedure to detect any tumor recurrence. RESULTS: There were no statistically significant differences between both techniques regarding complications, local tumor recurrence, development of de novo HCC lesions and changes in the modified Child-Pugh score. Time of ablation using MWA was significantly shorter than RFA (P<0.001). CONCLUSIONS: RFA and MWA are comparable techniques for HCC treatment. Our group couldn't prove any superiority of MWA over RFA except for the shorter time needed for ablation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。